Author Archives: Bruno Quinney

Close up of vaccine syringe
#Biopharma #Clinical trial #Tourette

First patient dosed with new Tourette syndrome therapy 

The first patient has been dosed in a trial for an investigational Tourette syndrome therapy.  Biopharmaceutical company Emalex Biosciences announced that the first patient was dosed in its expanded access programme for ecopipam, an investigational first-in-class D1 receptor antagonist in development for the treatment of Tourette syndrome.  … Read More

#News

#Drug discovery #Immunology #Nobel Prize #Osteoporosis #Systems biology

Meet the researcher: Mary Brunkow, Nobel winner 

Mary Brunkow PhD is Senior Program Manager at the Institute for Systems Biology in Seattle in the US. She was one of three co-winners of the 2025 Nobel Prize in Physiology or Medicine for the discovery of regulatory T cells (Tregs). She shares her career highlights and some word of wisdom with Diana Turner.  DT: What… Read More

#Exclusive Content #Opinion

#Ascendis Pharma #BioIndustry Association #Cancer therapy #CHMP #Clinical trial #Diversity #European Medicines Agency #FDA #Gene therapy #Oncology #Paediatrics #Rare disease #uniQure #University of Queensland #Women in STEM

DDW Highlights: 10 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, figures showed the number of women in biotech leadership has stalled. Elsewhere, could… Read More

#Podcasts

#Brain #Institute of Cancer Research #Tumour biology

Brain imaging platform could ‘accelerate’ tumour treatment 

An advanced imaging platform could “accelerate” the treatment of childhood brain tumours, research reveals.  Scientists at The Institute of Cancer Research, London have developed a new preclinical platform for studying aggressive childhood brain tumours, using advanced imaging to show how closely experimental models mirror the disease seen… Read More

#Cancer Research #News

#DNA technology #Gene synthesis #Gene therapy #Protein design

Cell-free DNA programme could ‘empower’ therapeutics to market

A newly accessible cell-free DNA programme could “empower” therapeutics to market, the CEO of Ribbon Bio has said. Jodi Barrientos, CEO of the synthetic biology company, was speaking at the ‘Engineering Biology: DNA and Beyond’ conference in Vienna, Austria, which took place on the 5 and 6 March. At the… Read More

#News

Liquid handler in laboratory
#Genomics #Sample preparation #SPT Labtech

SPT Labtech and Illumina to develop genomics platform 

SPT Labtech has announced a strategic collaboration with Illumina to develop a novel automated sample preparation platform in genomics.  The platform, designed to streamline and standardise genomics workflows across decentralised healthcare environments, will support laboratories using Illumina’s MiSeq i100 benchtop sequencing system. The system offers more accessible high-quality next-generation sequencing… Read More

#Business & Investment #News

Human liver
#Fibrotic disease #In Conversation Series #Liver disease #Resolution Therapeutics

Is the future of liver disease treatment about to change?

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Amir Hefni, CEO of Resolution Therapeutics. Resolution specialises in developing therapies for inflammatory and fibrotic diseases and is currently progressing a treatment for end-stage liver… Read More

#Featured Podcasts #Podcasts

Genetic research
#Genetic diseases #Genomics

Genomics technology could ‘end diagnostic odysseys’   

Illumina has launched its TruPath Genome to provide researchers with a more complete picture of genomics alterations in genetic disease.  The company claims the technology fully phases more than 98% of genes, eliminating traditional library prep and generating 16 whole genomes per day in 10 minutes of hands-on time. … Read More

#News

The European Medicines Agency building
#CHMP #Clinical trial #European Medicines Agency

CHMP issues positive opinion on CSU targeted therapy 

The European Medicines Agency (EMA)’s Committee for Medicinal Products (CHMP) has adopted a positive opinion recommending marketing authorisation for a chronic spontaneous urticaria (CSU) treatment.  The opinion means remibrutinib, a highly selective oral BTKi developed by Novartis, could be the first targeted therapy approved for CSU in Europe. … Read More

#News #Regulatory

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Prostate cancer #UK #ViiV Healthcare

DDW Highlights: 3 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, more effective treatments were found for both HIV and chronic wounds. Elsewhere, €40,000… Read More

#Podcasts

#Autoimmune disease #Drug discovery #Infectious diseases

Asahi Kasei Pharma strengthens drug discovery pipeline 

Asahi Kasei Pharma has announced a global license agreement with Alchemedicine to strengthen its drug discovery pipeline.  The agreement means Asahi Kasei Pharma can research, develop, manufacture, and commercialise Alchemedicine’s novel lead compounds, which are currently at the preclinical stage.  The compounds were identified using Alchemedicine’s drug discovery platform, HiSAP1 and are expected to… Read More

#Business & Investment #News

Sickle cells
#Beam Therapeutics #Genetic diseases #Sickle cells

Beam expands liver-targeted genetic disease programme 

Biotechnology company Beam Therapeutics is set to expand its liver-targeted genetic disease franchise for the treatment of phenylketonuria (PKU).  Beam’s lead programme, BEAM-304, leverages the company’s proprietary and clinically validated base editing technology and lipid nanoparticle (LNP) delivery capabilities to directly and durably correct mutations in the phenylalanine… Read More

#News

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #GLP-1 #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Obesity #Prostate cancer #UK #ViiV Healthcare #Weight loss

This week in Drug Discovery (23 – 27 February) 

News round-up for 23 – 27 February by Bruno Quinney, Content Team at DDW.  This week in drug discovery, more effective treatments have been found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research.  The top stories:   … Read More

#News